ATE186732T1 - (e)-2'-deoxy-2'-(fluormethylen)cytidin-monohydr t - Google Patents
(e)-2'-deoxy-2'-(fluormethylen)cytidin-monohydr tInfo
- Publication number
- ATE186732T1 ATE186732T1 AT95907232T AT95907232T ATE186732T1 AT E186732 T1 ATE186732 T1 AT E186732T1 AT 95907232 T AT95907232 T AT 95907232T AT 95907232 T AT95907232 T AT 95907232T AT E186732 T1 ATE186732 T1 AT E186732T1
- Authority
- AT
- Austria
- Prior art keywords
- fluoromethylene
- cytidine
- deoxy
- monohydr
- neoplastic
- Prior art date
Links
- GFFXZLZWLOBBLO-ASKVSEFXSA-N tezacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(=C/F)/[C@H](O)[C@@H](CO)O1 GFFXZLZWLOBBLO-ASKVSEFXSA-N 0.000 title abstract 2
- 229940123934 Reductase inhibitor Drugs 0.000 abstract 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 abstract 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000004682 monohydrates Chemical class 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17895294A | 1994-01-07 | 1994-01-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE186732T1 true ATE186732T1 (de) | 1999-12-15 |
Family
ID=22654587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95907232T ATE186732T1 (de) | 1994-01-07 | 1994-12-13 | (e)-2'-deoxy-2'-(fluormethylen)cytidin-monohydr t |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP0738273B1 (de) |
| JP (1) | JPH09511227A (de) |
| KR (1) | KR100330328B1 (de) |
| CN (1) | CN1043231C (de) |
| AT (1) | ATE186732T1 (de) |
| AU (1) | AU684604B2 (de) |
| CA (1) | CA2179987C (de) |
| DE (1) | DE69421721T2 (de) |
| DK (1) | DK0738273T3 (de) |
| ES (1) | ES2141330T3 (de) |
| FI (1) | FI114396B (de) |
| GR (1) | GR3032614T3 (de) |
| HU (1) | HU217849B (de) |
| IL (1) | IL112242A (de) |
| MX (1) | MX9500363A (de) |
| NO (1) | NO306409B1 (de) |
| NZ (1) | NZ279030A (de) |
| TW (1) | TW397838B (de) |
| WO (1) | WO1995018815A1 (de) |
| ZA (1) | ZA9512B (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100540046B1 (ko) | 1997-11-12 | 2006-01-10 | 미쓰비시 가가꾸 가부시키가이샤 | 퓨린유도체 및 이를 유효성분으로 함유하는 의약 |
| KR100747106B1 (ko) | 1999-05-11 | 2007-08-08 | 미쯔비시 가가꾸 가부시끼가이샤 | 퓨린 유도체 이수화물, 이를 유효성분으로 함유하는 의약및 이의 제조 중간체 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2002648C (en) * | 1988-11-15 | 2000-02-29 | James R. Mccarthy | 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives |
| FI95269C (fi) * | 1989-05-15 | 1996-01-10 | Squibb Bristol Myers Co | 2',3'-dideoksi-inosiinimonohydraatin, 2',3'-dideoksi-2',3'-didehydrot ymidiinimonohydraatin ja 2',3'-dideoksi-2'-fluori-inosiinihemihydraatin antiviraalisia, hyvin vesiliukoisia, stabiileja, kiteisiä suoloja |
| JPH0615557B2 (ja) * | 1990-02-19 | 1994-03-02 | ヤマサ醤油株式会社 | ２’―デオキシ―２’―メチリデンシチジンの２水和物結晶 |
| AU662630B2 (en) * | 1992-05-12 | 1995-09-07 | Aventis Inc. | A process for the preparation of ribonucleotide reductase inhibitors |
-
1994
- 1994-12-13 AT AT95907232T patent/ATE186732T1/de not_active IP Right Cessation
- 1994-12-13 DE DE69421721T patent/DE69421721T2/de not_active Expired - Fee Related
- 1994-12-13 CA CA002179987A patent/CA2179987C/en not_active Expired - Fee Related
- 1994-12-13 CN CN94194779A patent/CN1043231C/zh not_active Expired - Fee Related
- 1994-12-13 KR KR1019960703658A patent/KR100330328B1/ko not_active Expired - Fee Related
- 1994-12-13 JP JP7518503A patent/JPH09511227A/ja active Pending
- 1994-12-13 HU HU9601848A patent/HU217849B/hu not_active IP Right Cessation
- 1994-12-13 DK DK95907232T patent/DK0738273T3/da active
- 1994-12-13 EP EP95907232A patent/EP0738273B1/de not_active Expired - Lifetime
- 1994-12-13 NZ NZ279030A patent/NZ279030A/en unknown
- 1994-12-13 WO PCT/US1994/014648 patent/WO1995018815A1/en not_active Ceased
- 1994-12-13 ES ES95907232T patent/ES2141330T3/es not_active Expired - Lifetime
- 1994-12-13 AU AU15532/95A patent/AU684604B2/en not_active Ceased
-
1995
- 1995-01-03 ZA ZA9512A patent/ZA9512B/xx unknown
- 1995-01-04 TW TW084100012A patent/TW397838B/zh not_active IP Right Cessation
- 1995-01-04 IL IL11224295A patent/IL112242A/xx not_active IP Right Cessation
- 1995-01-06 MX MX9500363A patent/MX9500363A/es unknown
-
1996
- 1996-07-05 NO NO962848A patent/NO306409B1/no unknown
- 1996-07-05 FI FI962769A patent/FI114396B/fi active IP Right Grant
-
2000
- 2000-02-09 GR GR20000400313T patent/GR3032614T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FI962769L (fi) | 1996-07-05 |
| HU217849B (hu) | 2000-04-28 |
| EP0738273B1 (de) | 1999-11-17 |
| NZ279030A (en) | 1997-05-26 |
| EP0738273A1 (de) | 1996-10-23 |
| NO962848L (no) | 1996-09-06 |
| IL112242A0 (en) | 1995-03-30 |
| FI114396B (fi) | 2004-10-15 |
| DE69421721T2 (de) | 2000-04-27 |
| AU684604B2 (en) | 1997-12-18 |
| HU9601848D0 (en) | 1996-09-30 |
| DK0738273T3 (da) | 2000-04-17 |
| ES2141330T3 (es) | 2000-03-16 |
| CA2179987C (en) | 1999-01-19 |
| GR3032614T3 (en) | 2000-05-31 |
| HUT75055A (en) | 1997-03-28 |
| CN1043231C (zh) | 1999-05-05 |
| WO1995018815A1 (en) | 1995-07-13 |
| TW397838B (en) | 2000-07-11 |
| DE69421721D1 (de) | 1999-12-23 |
| IL112242A (en) | 2000-08-31 |
| JPH09511227A (ja) | 1997-11-11 |
| MX9500363A (es) | 1998-04-30 |
| ZA9512B (en) | 1995-09-11 |
| AU1553295A (en) | 1995-08-01 |
| NO962848D0 (no) | 1996-07-05 |
| CA2179987A1 (en) | 1995-07-13 |
| FI962769A0 (fi) | 1996-07-05 |
| KR100330328B1 (ko) | 2002-12-05 |
| NO306409B1 (no) | 1999-11-01 |
| CN1141045A (zh) | 1997-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR199701212T1 (xx) | �drar� tutamama halinin tedavisi i�in alfa IL- agonistlerinin kullan�lmas�. | |
| SE9500566D0 (sv) | L-plate | |
| BR9506667A (pt) | Composto intermediário de cloro-pirimidina processo para a preparação do composto intermediário de cloro-pirimidina processo para a preparação de 2,5-diamino-4,6-dicloro-pirimidina processo para a preparação de 2,6-diamino-purinas e processo para a preparação de (1s,4s)-4-2-amino-6-(ciclo-propil-amino)-9h-purin-9-il¾-2-ciclo-penteno-1-metanol | |
| EA200100541A1 (ru) | Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину и других антидиабетических агентов | |
| ES2191292T3 (es) | Compuestos antivirales poliaromaticos. | |
| ATE186732T1 (de) | (e)-2'-deoxy-2'-(fluormethylen)cytidin-monohydr t | |
| CA2002648A1 (en) | 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives | |
| IT1273751B (it) | Derivati azaciclici | |
| DK630589D0 (da) | 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor-sammensaetning | |
| ATE201680T1 (de) | 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze | |
| BR9811643A (pt) | Suplementação quìmica de osso | |
| BR9810616A (pt) | Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer | |
| MY124071A (en) | Treatment of viral disease in swine | |
| AU3170193A (en) | Therapeutic nucleosides | |
| MC1930A1 (fr) | Produit antiviral | |
| BR9916043A (pt) | Composto, uso do mesmo e de seus saisfarmaceuticamente aceitáveis, e, composiçãofarmacêutica para tratamento de infecções deherpes viral em pacientes | |
| ES8704962A1 (es) | Un procedimiento para preparar 1b-d-ribofuranosil, 1-2-4-triazol-3-carboxamida. | |
| BR9808564A (pt) | Método de tratar um paciente tendo infecções por hiv | |
| DK0459176T3 (da) | Oligophosphater med antiviral virkning | |
| ES2085023T3 (es) | Procedimientos para la produccion de zidovudina. | |
| BR0012380A (pt) | 2-amino-benzoxazinonas para o tratamento de vìrus do herpes simples | |
| AR015724A1 (es) | La utilizacion de un inhibidor del intercambiador entre na+ y h+ para la preparacion de un medicamento destinado al tratamiento o a la profilaxia deenfermedades del sistema nervioso central. | |
| SE9403861D0 (sv) | Novel medicinal use | |
| BR9906931A (pt) | Triazepinonas, processo para sua preparação e sua aplicação terapêutica | |
| ES2181160T3 (es) | Derivados de 1,4-dihidropiridina y su utilizacion en terapia. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |